<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02320877</url>
  </required_header>
  <id_info>
    <org_study_id>B300201422483</org_study_id>
    <nct_id>NCT02320877</nct_id>
  </id_info>
  <brief_title>Evaluation of the Cardiovascular Effects of the MAS in the Treatment of Obstructive Sleep Apnea</brief_title>
  <official_title>Evaluation of the Overall Effectiveness Including Cardiovascular Effects of the Custom-made, Titratable Duoblock Flex SomnoDent® MAS in the Treatment of Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective trial 50 patients, diagnosed with moderate to severe obstructive sleep
      apnea (OSA) (AHI &gt; 15/h sleep) will be included and treated with mandibular advancement
      devices (MAD). These patients will undergo cardiovascular examination; echocardiography and
      24h-blood pressure monitoring, on top of the normal clinical evaluation of OSA patients.
      These cardiovascular examinations will take place before and during MAD therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular outcome</measure>
    <time_frame>6 months</time_frame>
    <description>interventricular septum thickness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiovascular outcome</measure>
    <time_frame>6 months</time_frame>
    <description>ventricular dilatation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiovascular outcome</measure>
    <time_frame>6 months</time_frame>
    <description>cardiac strain. This will be measured on speckle tracking echocardiopgraphy (STE). STE is an echocardiographic imaging technique that analyzes the motion of heart tissue by using ultrasound waves to generate interference patterns and natural acoustic reflections. These reflections, also described as ''speckles'', are tracked consecutively frame to frame and ultimately resolved into angle-independent two-dimensional and three-dimensional strain-based sequences (3D). These sequences provide both quantitative and qualitative information regarding heart tissue deformation and motion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiovascular outcome</measure>
    <time_frame>6 months</time_frame>
    <description>stroke volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OSA efficacy: apnea-hypopnea index</measure>
    <time_frame>6 months</time_frame>
    <description>benefit in apnea-hypopnea index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy compliance</measure>
    <time_frame>6 months</time_frame>
    <description>Therapy compliance will be objectively monitored12 using 2 microsensors (Dentitrac®, Braebon Medical Corporation, Kanata, Ontario, Canada; TheraMon, IFT Handels- und Entwicklungsgesellschaft GmbH, Handelsagentur Gschladt, Hargelsberg, Austria) embedded in the OAm as well as by self-reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy on subjective complaints: epworth sleepiness scale</measure>
    <time_frame>6 months</time_frame>
    <description>daytime sleepiness measured using epworth sleepiness scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy on subjective complaints: visual analogue scale for snoring</measure>
    <time_frame>6 months</time_frame>
    <description>visual analogue scale for snoring</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>OSA</condition>
  <arm_group>
    <arm_group_label>Mandibular Advancement Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mandibular advancement Devices are worn intra-orally at night in order to advance the mandible and to reduce the collapsibility of the upper airway.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mandibular Advancement Device (Somnomed Flex)</intervention_name>
    <description>The SomnoDent Flex™ MAS is a custom-made, titratable MAS that is validated in randomized controlled trials described in literature</description>
    <arm_group_label>Mandibular Advancement Device</arm_group_label>
    <other_name>Somnomed Flex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AHI &gt; 15 events/hour

          -  No other active OSA therapy in the 3 months preceding inclusion

          -  Willing to participate after informed consent

          -  Positive advice on OAT after DISE

        Exclusion Criteria:

          -  Insufficient teeth to support the device

          -  Periodontal problems including tooth mobility

          -  Active temporomandibular joint dysfunction

          -  Limited maximum protrusive capacity (&lt; 6 mm)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier Vanderveken, Phd, MD</last_name>
    <phone>0032 3 821 338</phone>
    <email>olivier.vanderveken@uza.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc J Braem, DDS, PhD</last_name>
      <phone>0032 3 821 3389</phone>
      <email>marc.braem@ua.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Olivier M Vanderveken, MD, PhD</last_name>
      <phone>0032 3 821 3385</phone>
      <email>olivier.vanderveken@uza.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2014</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Ethisch Comité UZA</investigator_full_name>
    <investigator_title>Ethisch Comité UZ Antwerpen</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methaqualone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

